Format

Send to

Choose Destination
See comment in PubMed Commons below
J Pediatr Hematol Oncol. 2009 Nov;31(11):873-8. doi: 10.1097/MPH.0b013e3181b83cab.

Decision analysis of treatment strategies in children with severe sickle cell disease.

Author information

1
Center for Innovation in Pediatric Practice, The Research Institute at Nationwide Children's Hospital, Columbus, OH 43205, USA. sarah.obrien@nationwidechildrens.org

Abstract

We designed a decision analysis model comparing 4 treatment strategies for severe sickle cell disease: no intervention, hydroxyurea (HU), chronic transfusion, or stem cell transplant (SCT). The treatment strategy associated with the highest average utility (quality of life) was SCT (0.85). Average utilities for no treatment, chronic transfusion, and HU were 0.68, 0.71, and 0.80, respectively. Our model was quite sensitive to quality-of-life estimates, indicating that a true comparison of HU and transplantation cannot occur until investigators directly measure the health-related quality of life in children with sickle cell disease during HU therapy and after SCT.

PMID:
19829150
PMCID:
PMC4486015
DOI:
10.1097/MPH.0b013e3181b83cab
[Indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Wolters Kluwer Icon for PubMed Central
    Loading ...
    Support Center